Menu Back toStatistical-Challenges-in-Assessing-Drugs-Efficacy-by-Utilizing-Biomarker-Endpoints

DIA 2018 Global Annual Meeting


Statistical Challenges in Assessing Drugs’ Efficacy by Utilizing Biomarker Endpoints

    Session Chair(s)
      Aloka  Chakravarty, PhD

      Aloka Chakravarty, PhD

      • Acting Deputy Director, Office of Biostatistics, OTS, CDER
      • FDA, United States
    This session will provide a platform for researchers to discuss the challenges and issues they faced, share the lessons they learned, and offer possible strategies for future development programs in assessing drug's efficacy by utilizing biomarkers.
    Learning Objective : Discuss the challenges and issues, share the lessons learned, and offer possible strategies for future development programs in assessing drug's efficacy by utilizing biomarker endpoints.
    Speaker(s)
      Haoda  Fu

      Individualized Treatment Recommendation Through Machine Learning Algorithms

      Haoda Fu

      • Senior Research Scientist
      • Eli Lilly and Company, United States
      Bettina  Hansen

      Validation of Biomarkers as a Surrogate for Clinical Endpoints: The Global PBC Experience

      Bettina Hansen

      • Senior Biostatistician of Clinical Research Studies
      • Institute of Health Policy, Management and Evaluation (IHPME), University of Tor, Canada
      Aloka  Chakravarty, PhD

      Assessment of Concordance Between BNiomarkers and Clinical Outcomes Response to Drug Interventions

      Aloka Chakravarty, PhD

      • Acting Deputy Director, Office of Biostatistics, OTS, CDER
      • FDA, United States